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Background: Nova Scotia has one of the highest incidences of inflammatory bowel disease (IBD) in the world. We
wished to determine trends of IBD over time.
Methods: All Provincial residents have government provided health insurance and all interactions with the hospital,
and physician billing systems, are captured on an administrative database. We used a validated measure to define
incident cases of Crohn’s (CD), ulcerative colitis (UC) and undifferentiated IBD (IBDU). Incidence rates of these
diseases for the years 1996–2009 were calculated.
Results: Over the study period, 7,153 new cases of IBD were observed of which 3,046 cases were categorized as
CD (42.6%), 2,960 as UC (41.4%) and 1,147 as IBDU (16.0%). Annual age standardized incidence rates were very high
but have declined for CD from 27.4 to 17.7/100,000 population and for UC from 21.4 to 16.7/100,000. The decline
was seen in all age groups and both genders. The decrease was not explained by a small increase in IBDU.
Conclusion: The incidence of CD and UC are decreasing in Nova Scotia. If replicated elsewhere this indicates a
reversal after a long period of increasing occurrence of IBD. This has implications for both epidemiology and health
planning.
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Inflammatory bowel disease (IBD) is a gastrointestinal
disorder which consists of Crohn’s Disease (CD), Ulcerative
Colitis (UC) and Undifferentiated IBD (IBDU). IBDU is
diagnosed when the illness has features of both CD and
UC [1].
The aetiology of these conditions remains unclear
[2-6]. Incidence and prevalence rates are rising in many
regions of the world including developing nations [2].
Escalating rates have led to an increased awareness of
IBD given the significant burden of morbidity and high
economic costs associated with it.
The prevalence and incidence of IBD has been studied
extensively in recent years. The disease affects both
genders and all ages. Molodecky et al. [3] conducted a* Correspondence: dleddin@Dal.Ca
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compared CD and UC rates across regions and over time.
The incidence and prevalence were highest in western
nations, specifically Northern Europe and Canada.
In Canada studies have been conducted to describe
patterns of IBD occurrence within this country. Bernstein
et al. [7] analyzed data from five provinces and extrapo-
lated to produce nationwide incidence and prevalence
estimates for both CD and UC. Consistent with other
studies, there were considerable differences in rates
across regions. The age adjusted incidence of Crohn’s
disease in Canada varied from 8.8/100,000 population
in British Columbia to 20.2/100,000 in Nova Scotia.
The incidence of IBD varies with time [8,9]. Such changes
may help identify factors contributing to the pathogenesis
of the disease. Therefore it is important to measure a
baseline and track changes over time using reliable and
consistent data sources. The objective of this study was to
determine the incidence of CD, UC and IBDU in NovaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 The database criteria for the diagnosis of IBD,
UC, CD and IBDU
IBD All patients had to have at least one hospitalization, or four
physician claims, within a two year period for a diagnosis
of IBD.
• IBD patients were then classified as UC, CD or IBDU as follows.
• Each medical contact for the Physician Billing claims database
was scored as + 1 (UC) or −1 (CD).
• Each medical contact for the Discharge Abstract database was
scored as +2 (UC) or −2 (CD).
• A cumulative score was calculated for each patient.
UC Patients with a cumulative score greater than +2.
CD Patients with a cumulative score less than −2.
IBDU Patients with a cumulative score equal to, or between, −2
and +2.
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incidence over time.
Methods
Nova Scotia is located on the east coast of Canada and
has advantages as a location for the study of incidence
trends in IBD. The population is ethnically homogenous,
and there is little in- or out-migration [10]. The province
has a population of just over 920,000 which is of sufficient
size to yield enough cases to make meaningful inferences
about changes in incidence, the population is equally
divided between rural and urban areas, has a high
background incidence and prevalence of the diseases
[7], and it has universal health care in which all residents
of the province receive necessary health care regardless of
their ability to pay. All residents have a health card, which
is used when accessing care. All encounters with the
health system are captured on a government database,
and it has a population health research unit, which has ac-
cess to all health encounter data. This is not a registry
study but is based on health utilization data which cap-
tures every resident of the Province.
Data collection
The data for this study were based on the Nova Scotia
administrative health care databases. All residents of the
Province have publicly funded health insurance for
physician and hospital care. Billings generated by pa-
tient interactions with hospital or physician services
are submitted to the government for payment using
unique patient identifiers. The Provincial Insurance
payments database was used to determine Nova Scotia
Medical Service Insurance eligibility, and for patient
demographics. The Canadian Institute for Health In-
formation Discharge Abstract database and Physician
Billings claims database were used to obtain diagnosis
and procedure codes for IBD. Records for the calendar
years 1991 to 2010 inclusive were used.
The definition of IBD was based on a modification of
the validated administrative case definition from Alberta
[11] with a reported sensitivity and specificity of 77.9%
and 99.8% respectively. Based on this case definition,
Physician Claims and hospital Discharge Abstracts data-
bases were searched for a diagnosis of IBD (i.e. ICD-9 codes
of 555.x or 556.x; and ICD-10 codes of K50.x or K51.x).
Case definitions for CD (sensitivity of 91.1% and specifi-
city of 98.7%) and UC (sensitivity of 81.7% and specificity
of 97.4%) were also based on the validation study by
Rezaie et al. [11] Within each administrative database
(i.e. Discharge Abstract and Physician Billings claims
databases) patients were given a +1 score for each ICD
diagnostic code for UC (ICD-9 code 556.x, ICD-10
code K51.x) or a score of −1 for each ICD code for CD
(ICD-10 code 555.x, ICD-10 code K50.x).The diagnostic criteria are shown in Table 1. A patient
with one hospitalisation or four physician claims would
meet the criteria for a diagnosis of IBD. Following the
diagnosis of IBD patients were sub classified by IBD
type. If, for example, the patient had one hospitalisation
with a discharge diagnosis of UC and one physician claims
with a diagnosis of UC their cumulative score would be
(+2 for the hospital discharge) + (+1 for the physician
billing) = +3.
Since some subjects may not have been seen every
year, incidence rates were calculated after excluding any
subject with a physician billing or hospital discharge
records with a diagnosis of the target diagnoses between
1991 and 1995. Hence, incidence rates were reported for
the year 1996–2009. Date of first medical contact was
considered the “diagnosis date” for estimating incidence
rates.
Statistical analysis
The total number of incident cases of CD, UC and IBDU
were calculated for women and men and by age group.
To adjust for age distribution and compare across years,
directly age-standardized incidence rates of CD, UC and
IBDU were calculated for women and men and overall.
The 2006 Canadian population was used as the standard
population. All rates were reported per 100,000 persons.
Poisson regression was used to measure the effect of cal-
endar year on the incidence of CD, UC, IBDU and IBD
for each sex by age groups and overall. Year was in-
cluded in the model as a categorical variable with the
year 1996 being the reference category. Analysis was
conducted using SAS 9.1 software [12].
Ethics approval
This study was approved by the Dalhousie University ethics
committee and by the Capital District Health Authority
ethics committee and is in compliance with the Helsinki
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by Health Data Nova Scotia, and was approved by the
access committee following review of the application and
receipt of ethics approval.
Results and discussion
Over the 14 year period under study, across all age
groups and both genders, a total of 7,153 incident cases
of IBD were identified with 3,046 cases categorized as
CD (42.6%), 2,960 cases categorized as UC (41.4%) and
1,147 cases categorized as IBDU (16.0%).
With regard to the 3,046 incident cases of CD, 1,743
(57.2%) were in women and 1,303 (42.8%) were in men
whereas of the 2,960 incident cases of UC, 1,507 (50.9%)
were in women and 1,453 (49.1%) in men. Of the 1,147
incident cases of IBDU, 617 (53.8%) were in women and
530 (46.2%) in men. Over 50% of the incident cases of
IBD in men and women occurred among ages 20–59
years (Table 2).Table 2 Total number (%) of incident cases of CD, UC and
IBDU in Nova Scotia, 1996-2009
CD UC IBDU
Age group (years) N % N % N %
Women
<10 23 1.3 12 0.8 4 0.6
10-19 193 11.1 102 6.8 20 3.2
20-29 397 22.8 212 14.1 76 12.3
30-39 364 20.9 316 21.0 103 16.7
40-49 267 15.3 309 20.5 97 15.7
50-59 237 13.6 244 16.2 101 16.4
60-69 148 8.5 168 11.1 80 13.0
70-79 83 4.8 94 6.2 82 13.3
≥ 80 31 1.8 50 3.3 54 8.8
All women 1743 100.0 1507 100.0 617 100.0
Men
<10 25 1.9 14 1.0 2 0.4
10-19 221 17.0 97 6.7 27 5.1
20-29 285 21.9 183 12.6 74 14.0
30-39 251 19.3 252 17.3 85 16.0
40-49 218 16.7 301 20.7 78 14.7
50-59 156 12.0 265 18.2 106 20.0
60-69 92 7.1 194 13.4 77 14.5
CD UC IBDU
Age group (years) N % N % N %
70-79 43 3.3 112 7.7 57 10.8
≥ 80 12 0.9 35 2.4 24 4.5
All men 1303 100.0 1453 100.0 530 100.0
Abbreviations: CD Crohn’s disease, IBDU Undifferentiated inflammatory bowel
disease, UC Ulcerative colitis.The directly age-standardized rates of CD, UC and
IBDU allowed for comparisons across years with adjust-
ment for age distribution over time. Decreases in inci-
dence were observed both for women (CD from 31.5 to
19.1/100,000 and UC from 20.3 to 16.9/100,000) and men
(CD 23.0 to 16.3 and UC from 22.6 to 16.6 per 100,000)
over the study period. Age-standardized rates of IBDU in-
creased both for women (from 8.4 to 12.1) and men (from
6.2 to 10.4) over study period (Table 3 and Figure 1).
The results in Table 3 are not based on the regression
model. It is descriptive and we cannot make inference as
to whether there is significant difference in incidence
over time. The percent differences in incidence rate with
time that is calculated from Table 4 are based on the
Poisson regression where the outcome follows a Poisson
distribution.
Results of the Poisson regression showed that there
was a significant negative change in the overall age-
adjusted rates relative to 1996 for CD and UC (Table 4).
Among sexes combined, the decrease for CD was 32.5%
(95% CI, −39.8 to −24.2) and for UC 24.8% (95% CI, −33.2
to −15.3). In men, the decrease for CD was 32.9% (95%
CI, −43.8 to −19.9) and for UC 29.0% (95% CI, −40.3
to −15.6). In women, the decrease for CD was 31.9%
(95% CI, −41.6 to −20.7) and 20.0% (95% CI, −32.5 to −5.3)
for UC.
Figure 2 shows incidence rates for CD, UC and IBDU
over time for different age groups. For CD, a decrease inTable 3 Annual directly age-standardized incidence rates
per 100,000 of CD, UC and IBDU by sex in Nova Scotia,
1996-2009
Women Men Sexes combined
CD UC IBDU CD UC IBDU CD UC IBDU
Year
1996 31.5 20.3 8.4 23.0 22.6 6.2 27.4 21.4 7.3
1997 29.1 25.2 8.8 26.1 28.2 7.7 27.7 26.7 8.3
1998 30.2 22.1 11.5 21.3 26.1 9.1 25.9 24.1 10.3
1999 24.5 26.1 6.8 20.3 25.4 7.9 22.5 25.8 7.4
2000 28.2 23.9 8.1 17.6 27.8 8.0 23.1 25.8 8.1
2001 22.2 21.5 9.4 23.4 22.0 6.2 22.8 21.8 7.9
2002 25.2 20.9 9.0 21.5 20.0 9.5 23.4 20.4 9.3
2003 28.6 24.2 10.0 22.4 23.1 8.4 25.6 23.6 9.2
2004 22.6 23.1 6.8 16.2 21.3 8.5 19.4 22.2 7.6
2005 27.0 22.2 8.8 20.7 17.2 8.6 24.0 19.8 8.7
2006 23.2 21.3 7.5 15.7 21.8 8.1 19.5 21.6 7.8
2007 21.2 19.1 7.6 18.1 16.8 7.2 19.7 18.0 7.4
2008 21.1 19.8 10.4 15.1 25.3 8.4 18.2 22.5 9.4
2009 19.1 16.9 12.1 16.3 16.6 10.4 17.7 16.7 11.3
Abbreviations: CD Crohn’s disease, IBDU Undifferentiated inflammatory bowel
disease, UC Ulcerative colitis.
Figure 1 Age-standardized incidence rates of Crohn’s Disease (CD), Ulcerative Colitis (UC), Undifferentiated Inflammatory Bowel
Disease (IBDU) and Inflammatory Bowel Disease (IBD) in Nova Scotia, 1996–2009.
Table 4 Estimated age-sex specific percentage changes (95% confidence intervals) in rates of CD, UC, IBDU and IBD in
Nova Scotia, 1996-2009
CD UC IBDU IBD
% change (95%CI) % change (95%CI) % change (95%CI) % change (95%CI)
Women
<20 -25.7 (−69.7, 82) 40.1 (−59, 378) 48 (−91.5, 2487) -0.7 (−50.5, 99.3)
20-29 -45.8 (−77.9, 33) -37.8 (−81.7, 111.5) 20.9 (−84.1, 819.2) -38.1 (−68.7, 22.3)
30-39 -29.6 (−71.7, 75.3) -35.3 (−75.8, 72.9) -18.9 (−85.3, 347.7) -30.7 (−62.8, 29.2)
40-49 -16.9 (−68.3, 117.8) -11.3 (−63.8, 117.1) 23.7 (−75.1, 515.1) -9.3 (−50.6, 66.3)
50+ -28.5 (−55.9, 16) -14.2 (−45.8, 35.7) 8.7 (−40.9, 100) -15.2 (−36.7, 13.5)
All women (adjusted for age) -31.9 (−41.6, −20.7) -20 (−32.5, −5.3) 11.5 (−15.2, 46.6) -21.4 (−29, −13)
Men
<20 -19.9 (−64.1, 78.6) 111.7 (−36.4, 603.9) 126.6 (−82, 2753) 17.1 (−38.1, 121.5)
20-29 -46.9 (−81.2, 50.6) -43.4 (−84.5, 107.2) 78.4 (−76.8, 1269.4) -35.8 (−69.7, 35.9)
30-39 -27 (−75.6, 118.2) -15.5 (−71.6, 151.3) 31.3 (−79.8, 751.4) -15.4 (−58.5, 72.7)
CD UC IBDU IBD
% change (95%CI) % change (95%CI) % change (95%CI) % change (95%CI)
40-49 -37 (−78.2, 81.9) -46.8 (−78.5, 31.8) 68.6 (−71.9, 910.5) -34.2 (−65.3, 24.9)
50+ -20.1 (−58.2, 52.9) -32.7 (−57.4, 6.5) -11.3 (−55.8, 77.8) -25.1 (−46.2, 4.1)
All men (adjusted for age) -32.9 (−43.8, −19.9) -29 (−40.3, −15.6) 21.2 (−9.5, 62.4) -24.3 (−32.2, −15.5)
Sexes combined
<20 -22.6 (−57.5, 40.8) 71.4 (−27.3, 304) 108.3 (−69.2, 1307) 8.2 (−32.4, 73.3)
20-29 -46.4 (−72.8, 5.8) -40.5 (−75.5, 44.9) 46.3 (−65.2, 515.2) -37.2 (−62, 4)
30-39 -28.8 (−64.7, 43.6) -27.2 (−64.9, 51) 0.8 (−71.4, 254.9) -24.6 (−52.8, 20.5)
40-49 -26.6 (−64, 49.7) -31 (−63.5, 30.2) 42 (−57, 368.4) -22 (−49.8, 21.1)
50+ -25.8 (−49.7, 9.6) -24.2 (−45.1, 4.8) -1 (−37.4, 56.7) -20 (−35.7, −0.4)
Sexes combined (adjusted for age) -32.5 (−39.8, −24.2) -24.8 (−33.2, −15.3) 17 (−4, 42.6) -22.8 (−28.4, −16.8)
Abbreviations: CI Confidence Interval, CD Crohn’s disease, IBD Inflammatory bowel disease, IBDU Undifferentiated inflammatory bowel disease UC Ulcerative colitis.
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Figure 2 Annual incidence rates per 100,000 of Crohn’s Disease (CD), Ulcerative Colitis (UC) and Undifferentiated Inflammatory Bowel
Disease (IBDU) by Age, Nova Scotia, 1996–2009.
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For UC, a decrease in incidence rates was observed for all
age groups except for age group less than 20 years of age
where incidence rates increased over time period. On the
other hand, incidence rates of IBDU showed no consistent
change for different age groups over time.
Incidence rates of CD among youngest women in our
cohort were almost double the rates of UC. This trend
appears to level off for women 30 years of age and older
where rates of CD and UC became equal. The same
trend was not observed for men, where rates of CD were
higher than UC for those younger than 30 years of age.
The equalization of the ratio of CD Disease to UC occurred
at age of 30–39 years, at which point the ratio between CD
and UC reversed (Figure 3).
Using a proxy for the incidence of both CD and UC
we have shown evidence of a decrease in incidence of
approximately 32% and 25%, respectively, over a fourteen-
year period from 1996–2009. The decline was observed in
all age groups, for both diseases, and both genders with
the exception of a non-significant increasing trend in
ulcerative colitis under the age of 20.
Results of the present study showed that age-
standardized incidence rates of CD and UC for NS for
the years 1998–2000 were higher than those reported
by Bernstein et al. [7]. This is explained by differences
in the case definitions used for each of the studies. In
Bernstein et al. the IBD case definition required a patient
to have at least five physician claims or hospitalizations
for CD or UC if resident of the province for at least two
years (or at least three claims if resident of the province
for fewer than two years). In contrast, the definition of
IBD used here, based on Rezaie et al. [11], relied on atFigure 3 Ratio of incidence of Crohn’s Disease (CD) to Ulcerative Colileast one hospitalization or four physician claims with an
IBD diagnostic code within a 2-year period. Bernstein
et al. [5] note that their definition leads to an underesti-
mate of the incidence of IBD. Fransoo et al. [13] make
clear that the Bernstein et al. case definition is better for
estimating population prevalence than incidence of IBD.
In addition the definition of Rezaie et al. [11] but not that
of Bernstein et al. [5] captures cases best defined as IBDU.
Our definition of IBD may underestimate milder cases
who are not seen frequently, and therefore do not gener-
ate billing data, or who are not hospitalized.
The possibility of information bias is a concern. We
mitigated this by using a validated measure of health
care access to define incident cases [11]. We incorpo-
rated a wash out period of 5 years, to reduce the impact
of including prevalent cases. Most importantly this is a
comprehensive population based study. Improvements
in treatment may have led to a decrease in interactions
resulting in fewer patients meeting the definition. The
major change in management has been the introduction
of the biologics. Patients who are being treated with bio-
logics are seen regularly in follow up. We also consid-
ered whether our data simply shows regression to the
mean and consider this unlikely given the duration of
the decline extending, as it does, over a period of four-
teen years. The results could be secondary to reduced
access to care, or a reduction in colonoscopy. Data from
the Nova Scotia Department of Health (personal com-
munication) shows that the number of colonoscopies in
the Province increased by nearly 300% over the years of
the study. This would favour an increase in IBD diagno-
sis, and IBD related billings, rather than the decrease
observed.tis (UC) by Age in Nova Scotia, 1996–2009.
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standard definition of IBD which can be utilised for IBD
data base studies. A national study is required using a
standardized case definition to verify our results.
The numbers of new cases of CD and UC were almost
equal in our population but CD was more common in
younger age groups. The incidence CD and UC equalize
at age 50 years for women but for men over the age of
50 years UC was more common than CD. This is consist-
ent with the prevalence of these diseases observed in a US
population [14].
These results are in contrast to those reported in a
recent systematic review (3), which concluded that no
studies of CD disease, and only 6% of studies of UC,
have shown a significant decline in incidence. However,
there are few population-based studies of incidence over
time, and none of a population with a baseline incidence
comparable to ours. Even fewer studies have reported
incidence for the years beyond 2003. As can be seen
from Table 3 a small decline in incidence was evident by
2003 but is more obvious from 2003–2009.
While no studies have reported a significant decline in
CD several have shown either a small, non-significant
decrease [15-18] or a plateau of incidence [19]. The report
from Northern France, which described the incidence up
to 2007, showed that the incidence of CD peaked in 1999
and is trending slightly downwards since [19].
The incidence for ulcerative colitis in the younger age
groups showed a non significant trend upwards over the
period under study. The incidence of IBD in the paediat-
ric population has been reviewed [20]. Sixty percent of
studies reported an increasing incidence of CD and 20%
of studies reported a rise in UC. The results reported
here are consistent with those findings. It is possible that
genetic factors play a greater role in younger onset IBD
whereas environmental factors may be of greater import-
ance in older age onset disease.
We observed a small and non significant increase in
IBDU. Clinically IBDU is diagnosed when the disease has
features of both ulcerative colitis and Crohn’s disease [1].
Clinically IBDU may account for up to 12.6% of new cases
of IBD in children and from 6% to 11.5% of cases in adults
[21,22], a proportion similar to that observed in our study.
However we used a database scoring system to define
cases of IBDU, not a clinical definition, and this may
account for the relatively high percentage of IBDU
cases in this study. It is possible that some of these
cases are actually UC or CD but even if they were ascribed
to either group the total number of new cases of IBD
shows a decline.
There is little in- or out-migration to Nova Scotia
therefore the genetic pool is stable [10] and the results
may point to an environmental factor. One environmen-
tal change, with the potential to affect all residents, wasthe addition of folic acid to cereals starting in 1998. This
was done to reduce the incidence of neural tube defects
in newborns [23].
Conclusions
The evidence from this study indicates that incidence
rates of both CD and UC are declining. Similar studies
of secular trends in these conditions from other jurisdic-
tions will be of interest to determine if the decline is a more
universal observation. These results need to be replicated
in countries with a high incidence and they may only to
applicable to areas where the starting incidence is high. If
replicated elsewhere this indicates a reversal after a long
period of increasing occurrence of IBD. This has implica-
tions for both epidemiology and health planning.
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